Simona Bertoni

Parma, 43124, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases.

CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases.

Journal: Pharmaceutics

Published: April 08, 2026

Effects of CCL20/CCR6 Modulators in a T Cell Adoptive Transfer Model of Colitis.

Effects of CCL20/CCR6 Modulators in a T Cell Adoptive Transfer Model of Colitis.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 17, 2025

Functional and morphological characterisation of human colonoid-derived monolayers under inflammatory conditions.

Functional and morphological characterisation of human colonoid-derived monolayers under inflammatory conditions.

Journal: International journal of pharmaceutics

Published: July 01, 2025

Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth.

Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth.

Journal: ChemMedChem

Published: May 21, 2024

Exploring the potential of human intestinal organoids: Applications, challenges, and future directions.

Exploring the potential of human intestinal organoids: Applications, challenges, and future directions.

Journal: Life sciences

Published: May 01, 2024

Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa.

Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa.

Journal: International journal of antimicrobial agents

Published: May 12, 2023

An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro.

An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro.

Journal: Pharmaceutics

Published: February 08, 2023

Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis.

Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis.

Journal: European journal of pharmacology

Published: January 05, 2023

Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach.

Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach.

Journal: Biochemical pharmacology

Published: December 01, 2022

Discovery of small-molecules targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases.

Discovery of small-molecules targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases.

Journal: European journal of medicinal chemistry

Published: July 12, 2022

Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses.

Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses.

Journal: ChemMedChem

Published: July 09, 2021

UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling.

UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 04, 2021

Showing 1-12 of 33

Last Updated: 09/26/2026